GlassScriptPhysician profile
Jill M Olson
NPI 1346446903
$15,172.07
in general payments reported to CMS, 2019-2025
60 companies · $862 in 2025
The $862 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,415 · 2020: $1,474 · 2021: $3,893 · 2022: $3,200 · 2023: $1,536 · 2024: $790 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,799 · Consulting Fee: $325 · Education: $65.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,798.55 |
| Consulting Fee | $325.00 |
| Education | $65.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,756.62 | 2020-2024 | |
| Biogen, INC. | $1,323.59 | 2019-2025 | Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $1,217.57 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $1,062.37 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $836.03 | 2019-2021 | |
| Emd Serono, INC. | $778.51 | 2019-2024 | Mavenclad |
| Amgen INC. | $637.19 | 2019-2024 | Uplizna, Aimovig |
| Ucb, INC. | $605.72 | 2019-2025 | Nayzilam, Rystiggo |
| Mallinckrodt Hospital Products INC. | $474.90 | 2020-2024 | Acthar |
| Lilly USA, LLC | $454.46 | 2019-2024 | Reyvow, Emgality |
| Allergan, INC. | $411.81 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $376.51 | 2019-2024 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $372.72 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $346.30 | 2022 | |
| Tg Therapeutics, INC. | $319.98 | 2023-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.